Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma
#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians can now access plant-derived dronabinol as an alternative to synthetic formulations, potentially offering different bioavailability or tolerability profiles for patients requiring cannabinoid therapy for chemotherapy-induced nausea, appetite stimulation, or chronic pain. This market expansion increases supply chain options and may improve treatment accessibility for patients in the UK who have demonstrated clinical need for dronabinol but faced limited availability. The availability of multiple dronabinol sources through different manufacturing pathways could reduce costs and improve reliability of this established pharmaceutical intervention.
Dunbar Pharma has launched WaterClear THC, a plant-derived dronabinol active pharmaceutical ingredient (API), into the UK market through distribution partner IPS Pharma. This development expands the availability of pharmaceutical-grade THC sourced directly from cannabis plants rather than through synthetic manufacturing, potentially offering clinicians a standardized botanical alternative for formulating cannabinoid medications. The plant-derived approach may appeal to patients who prefer naturally sourced therapeutics and could provide manufacturers with greater flexibility in developing THC-containing products for indications where dronabinol is clinically indicated. As the UK continues to establish its cannabis-derived medicine regulatory framework, increased API availability from established manufacturers may improve product standardization and accessibility for licensed prescribers. Clinicians should monitor how plant-derived dronabinol APIs perform in terms of bioavailability, batch consistency, and clinical outcomes compared to existing synthetic options as more products utilizing this ingredient reach the market.
“Plant-derived dronabinol represents a meaningful step toward standardization and quality control in cannabinoid formulations, but we should be clear that the API itself isn’t new clinically—what matters is rigorous pharmacokinetic data and long-term safety outcomes in real populations, which we’re still building through peer-reviewed research.”
💊 The introduction of plant-derived dronabinol APIs into regulated markets represents a potential shift toward more standardized cannabinoid therapeutics, though clinicians should recognize that plant-derived and synthetic dronabinol remain pharmacologically equivalent for prescribing purposes. While improved manufacturing consistency and supply chain reliability may theoretically benefit patients requiring dronabinol for chemotherapy-induced nausea or appetite stimulation, the clinical outcomes are unlikely to differ meaningfully from existing approved formulations. Providers should remain aware that regulatory approval of a new API source does not establish additional clinical efficacy or safety advantages, and pharmaceutical distinctions may matter more for manufacturers than for patient care. The practical implication is straightforward: practitioners can continue using dronabinol according to established guidelines without altering dosing, monitoring, or patient counseling based on manufacturing origin, while staying alert to any future evidence suggesting meaningful clinical differentiation.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
